 |
|
 |
 |

Home > Company Index > Drugs > Drugs - Generic > SkyePharma PLC
 |
SkyePharma PLC |
 |
 |
 |
PROFILE |
 |
SkyePharma finds new ways to make the medicine go down. The company develops controlled-release drug-delivery systems that reduce side effects and allow for fewer daily doses; it also formulates generic and super-generic drugs (drugs that are difficult to replicate or that are improved versions of off-patent originals). The company makes the drug-delivery systems, generics, and new drugs under its own name and under contract to other companies. Clients include large pharmaceutical concerns such as GlaxoSmithKline and Abbott Laboratories. Through acquisitions, SkyePharma has been expanding its portfolio, which includes oral, injectable, inhalation, topical, and nanoparticulate solubilization technologies.
COMPETITION |
 |
ALZA Corporation (dossier)
Barr Laboratories, Inc. (BRL)
Elan Corporation, plc (ELN)
|
 |
STOCK ANALYSIS |
 |
FURTHER ANALYSIS
Advanced Charting
Deals
FINANCIAL OVERVIEW |
 |
Fiscal Year-End: December
2000 Sales (mil.): 36.30
1-Yr. Sales Growth: 26.5%
Employees: 373
Revenue per employee: $97,319.03
KEY PEOPLE |
 |
Michael Ashton
CEO
Donald Nicholson
CFO
CONTACT INFO |
 |
105 Piccadilly
London W1V 9FN, United Kingdom
Phone: 44-20-7491-1777
Fax: 44-20-7491-3338
Online: Web Site
|
 |
 |
 |
|
Hoover's Company Capsule
Copyright © 2001, Hoover's Inc. Austin, Texas.
For changes and updates, contact Hoover's directly.
|

|
 |
 |
|
 |